DESCRIPTION
This activity is offered on the 2nd and 4th Tuesdays from 7:00 - 8:00 a.m. in Mangurian 1602.

Multidisciplinary tumor board attended by members of the Urology, Medical Oncology, Radiation Oncology, pathology and radiology departments on the Florida campus to discuss complex cases of genitourinary cancers. 

TARGET AUDIENCE
This course is intended for physicians, fellows, residents, and all others interested in this clinical topic area.  

LEARNING OBJECTIVES
Upon completion of the activities, the participant should be able to: 

• Apply the current care standards and clinical practice guidelines to optimize the management of patients with genitourinary cancers.
• Review new, emerging, and novel therapeutic agents and treatment strategies, including ongoing clinical trials, and incorporate these into the management of patients with genitourinary cancers.
• Communicate the importance of multidisciplinary care and improve collaboration among the interprofessional oncology care team in the management of patients with genitourinary cancers.
   

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s): 

AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE SUMMARY
As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities.  All who are in a position to control the content are required to disclose all financial relationships with any ineligible company.   Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with ineligible companies:
Timothy D. Lyon, M.D. - Consulting - ImmunityBio

All relevant financial relationships have been mitigated. 

No relevant financial relationship(s) with ineligible companies:
Adam M. Kase, M.D., Albert N. Attia, M.D., Jennifer P. Johnson, P.A.-C., Kathryn S. Cardona, APRN, Andrew J. Zganjar, M.D., Deborah L. Arnold, Nancy D. Stork, and Dustin Layland (added 6/23/23)

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:
None

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.

Broker Code: 20-1051132

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded will appear on your Transcript.

COURSE DIRECTORS
Timothy D. Lyon, M.D., Adam M. Kase, M.D., Albert N. Attia, M.D., Jennifer P. Johnson, P.A.-C., Kathryn S. Cardona, APRN, Andrew J. Zganjar, M.D.